Indeed, based on this rationale, several randomized controlled trials are evaluating the effectiveness of ICBs targeting PD-(L)1 and CTLA-4 on HCC recurrence after curative treatments [24,25]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.